On May 8th, Johnson & Johnson announced that Darzalex (daratumumab) new indication has received FDA approval for the combined use of bortezomib, melphalan and prednisone for first-line treatment of newly diagnosed unfit autologous stem cell transplantation (ASCT) multiple myeloma patient. In this way, Darzalex began with the FDA approval in… Continue Reading Johnson’s blockbuster Darzalex has been upgraded to receive first-line treatment for multiple myeloma.